GSK plc (LON:GSK)
2,046.00
+8.00 (0.39%)
At close: Mar 9, 2026
GSK plc Revenue
In the year 2025, GSK plc had annual revenue of 32.67B GBP with 4.11% growth. GSK plc had revenue of 8.62B in the quarter ending December 31, 2025, with 6.17% growth.
Revenue
32.67B
Revenue Growth
+4.11%
P/S Ratio
2.50
Revenue / Employee
488.73K
Employees
66,841
Market Cap
81.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.67B | 1.29B | 4.11% |
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| Convatec Group | 1.81B |
| Hikma Pharmaceuticals | 2.49B |
| HUTCHMED (China) | 407.54M |
| Genus | 672.00M |
| Oxford Nanopore Technologies | 223.90M |
GSK plc News
- 6 hours ago - Former GlaxoSmithKline HQ in west London to be transformed into 1,500 new homes - Evening Standard
- 10 hours ago - GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million - WSJ
- 10 hours ago - GSK: Alfasigma To Acquire Rights To Develop, Manufacture, Commercialise Linerixibat - Nasdaq
- 11 hours ago - GSK licenses liver disease drug to Italy's Alfasigma - Reuters
- 3 days ago - Pay bonanza for blue chip bosses: Rolls-Royce chief 'Turbo' Tufan set for £24m as GSK's Walmsley scoops £15.7m - This is Money
- 4 days ago - Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss - The Guardian
- 4 days ago - SCYNEXIS Posts Narrower FY25 Loss, Advances Next-Gen Antifungal Pipeline - Nasdaq
- 4 days ago - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - Benzinga